{"ok":true,"api":{"name":"SAIMSARA Evidence Object Discovery API","version":"v1"},"mode":"doc_key","editorial_verification":{"status":"human_reviewed","trust_label":"machine_generated_human_reviewed","method":"World ID proof-of-human editorial account","scope":["clinical_integrity","reference_quality","scientific_coherence"],"verification_note":"This Evidence Object is machine-generated and human-reviewed. World ID is used to verify that editorial oversight was submitted by a unique human account.","does_not_mean":"World ID verifies proof-of-human editorial oversight; it does not independently certify the scientific truth of every claim."},"object":{"object_type":"saimsara_evidence_object_metadata","doc_key":"visceral::RAS_AND_KRAS_CANCER_PM","issue_slug":"visceral","doc_id":"RAS_AND_KRAS_CANCER_PM","title":"RAS and KRAS Inhibitors in Cancer Therapeutic Mechanisms and Resistance","doi":"10.62487/saimsaradc4d1e0f","doi_url":"https://doi.org/10.62487/saimsaradc4d1e0f","version":"2026-06-01","source_name":"PubMed","article_url":"https://saimsara.com/sessions/ras-kras-inhibitors-cancer-20260601-173519-dc4d1e0f/","image_url":"","topic_tags":"RAS inhibitors,KRAS inhibitors,KRAS-mutant cancer,Pan-KRAS inhibition,RAS(ON) inhibitors,Sotorasib resistance,MAPK signaling,Combination therapy,Colorectal cancer,Non-small cell lung cancer","keywords":["RAS inhibitors","KRAS inhibitors","KRAS-mutant cancer","Pan-KRAS inhibition","RAS(ON) inhibitors","Sotorasib resistance","MAPK signaling","Combination therapy","Colorectal cancer","Non-small cell lung cancer"],"metrics":{"included_all":1077,"included_original":703,"reference_index":308,"total_participants":74272},"discover_url":"https://saimsara.com/api/v1/discover.php?doc_key=visceral%3A%3ARAS_AND_KRAS_CANCER_PM","paid_evidence_url":"https://saimsara.com/api/v1/evidence.php?doc_key=visceral%3A%3ARAS_AND_KRAS_CANCER_PM","price":{"amount":"5.00","currency":"USD","units":5,"unit_amount":"1.00"},"payment_methods":["api_key","stripe_checkout","object_grant","x402"],"text_length":49981,"preview":"Results Key finding aligned to the query: Across the included original studies, the central finding is that RAS/KRAS inhibition in cancer is therapeutically actionable but is best understood as a systems-level intervention: direct mutant-selective, pan-KRAS, pan-RAS, and RAS(ON) inhibitors can suppress RAS-addicted tumors, yet durable control often requires anticipating adaptive RAS–MAPK pathway reactivation, receptor tyrosine kinase feedback, wild-type RAS compensation, and lineage- or tumor-state escape programs. Representative preclinical studies showed broad activity for RAS(ON) multiselective or pan-KRAS approaches, including RMC-7977 activity across RAS-addicted models and a non-covale…","trust_label":"machine_generated_human_reviewed","editorial_verification":{"status":"human_reviewed","trust_label":"machine_generated_human_reviewed","method":"World ID proof-of-human editorial account","scope":["clinical_integrity","reference_quality","scientific_coherence"],"verification_note":"This Evidence Object is machine-generated and human-reviewed. World ID is used to verify that editorial oversight was submitted by a unique human account.","does_not_mean":"World ID verifies proof-of-human editorial oversight; it does not independently certify the scientific truth of every claim."},"checkout":{"method":"POST","url":"https://saimsara.com/create_checkout_session.php","content_type":"application/x-www-form-urlencoded","params":{"plan":"evidence_object","doc_key":"visceral::RAS_AND_KRAS_CANCER_PM"},"optional_params":{"customer_email":"user@example.com"},"price":{"amount":"5.00","currency":"USD","units":5,"unit_amount":"1.00"},"curl_example":"curl -X POST https://saimsara.com/create_checkout_session.php -d \"plan=evidence_object\" -d \"doc_key=visceral::RAS_AND_KRAS_CANCER_PM\" -d \"customer_email=user@example.com\""},"access_after_payment":{"header":"X-SAIMSARA-Payment-Proof","endpoint":"https://saimsara.com/api/v1/evidence.php?doc_key=visceral%3A%3ARAS_AND_KRAS_CANCER_PM","curl_example":"curl -H \"X-SAIMSARA-Payment-Proof: YOUR_PAYMENT_PROOF_TOKEN\" \"https://saimsara.com/api/v1/evidence.php?doc_key=visceral%3A%3ARAS_AND_KRAS_CANCER_PM\""}}}